var data={"title":"Iodixanol: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Iodixanol: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6385?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=iodixanol-drug-information\" class=\"drug drug_general\">see &quot;Iodixanol: Drug information&quot;</a> and <a href=\"topic.htm?path=iodixanol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Iodixanol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708949\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Not for intrathecal use. Inadvertent intrathecal administration may cause death, convulsions/seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183727\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Visipaque</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9746694\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Visipaque</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1019840\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Radiological/Contrast Media, Nonionic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4150480\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=iodixanol-drug-information\" class=\"drug drug_general\">see &quot;Iodixanol: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> The concentration and volume of iodixanol to be used should be individualized depending upon age, weight, size of vessel, and rate of blood flow within the vessel.</p>\n    <p style=\"text-indent:0em;\">Pediatric: <b>Radiologic contrast enhancement: </b></p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Children &gt;1 year:  </p>\n    <p style=\"text-indent:0em;margin-left:4em;\">Intra-arterial: Cerebral, cardiac chambers and related major arteries, and visceral studies: <b>320 mg iodine/mL</b>: 1 to 2 mL/kg; not to exceed a total dose of 4 mL/kg </p>\n    <p style=\"text-indent:0em;margin-left:4em;\">IV: Contrast-enhanced computerized tomography or excretory urography: <b>270 mg iodine/mL</b>: 1 to 2 mL/kg; not to exceed a total dose of 2 mL/kg </p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Adolescents: <b>270 mg or 320 mg iodine/mL</b>: Intra-arterial, IV: Concentration and dose individualized based on injection site and study type; refer to product labeling. Maximum total dose of iodine: 80 g</p>\n    <p style=\"text-indent:0em;\">Adult: <b>Radiologic contrast enhancement:</b> <b>270 mg or 320 mg iodine/mL</b>: Intra-arterial, IV: Concentration and dose individualized based on injection site and study type; refer to product labeling. Maximum total dose of iodine: 80 g  </p>\n    <p style=\"text-indent:0em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling (not studied); use caution in severe impairment and in setting of combined renal and hepatic disease. Dialyzable (36% to 49% depending upon the membrane).</p>\n    <p style=\"text-indent:0em;\">\n      <b>Dosing adjustment in hepatic impairment:</b>  There are no dosage adjustments provided in the manufacturer's labeling. Use caution in patients with combined hepatic and renal disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183718\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Visipaque: 320 mg/mL (50 mL, 100 mL, 150 mL, 200 mL, 500 mL) [contains edetate calcium disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Visipaque: 270 mg/mL (50 mL, 100 mL, 150 mL, 200 mL) [pyrogen free; contains edetate calcium disodium, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Visipaque: 320 mg/mL (50 mL) [pyrogen free; contains edetate calcium disodium]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183714\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2529683\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV or intra-arterial: Administer without further dilution. <b>Not for intrathecal administration</b>. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Patients should be adequately hydrated prior to and following administration. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid infiltration. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; initiate hyaluronidase antidote (see Management of Drug Extravasations for more details); elevate extremity. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183726\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store between 20&deg;C and 25&deg;C (68&deg;F and 77&deg;F); excursions are permitted to 15&deg;C to 30&deg;C (59&deg;F and 86&deg;F). Protect from strong daylight and direct exposure to sunlight. Do not freeze or use if inadvertently frozen. May be stored in contrast media warmer at 37&deg;C (98.6&deg;F) for up to 1 month.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1019841\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intra-arterial (FDA approved in ages &gt;1 year and adults):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Iodixanol injection (270 mgI/mL) is indicated for intra-arterial digital subtraction angiography.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Iodixanol injection (320 mgI/mL) is indicated for angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intravenous (FDA approved in all ages &gt;1 year and adults):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Iodixanol injection (270 mgI/mL) is indicated for contrast enhanced computed tomography (CECT) imaging of the head and body, excretory urography, and peripheral venography.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Iodixanol injection (320 mgI/mL) is indicated for CECT imaging of the head and body, and excretory urography.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2087642\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">\n          <b>Not </b>for intrathecal use.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2087648\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, chest pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Altered sense of smell, headache, migraine, paresthesia, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema, pruritus, skin rash (nonurticarial)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased thyroid hormones (transient; premature infants and infants with underlying medical conditions may be more vulnerable), hypothyroidism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Dysgeusia, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Discomfort at injection site, pain at injection site, warm sensation at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute renal failure, anaphylactoid reaction, anaphylaxis, apnea (children), asthma, atrioventricular block (children), back pain, bundle branch block (children), cardiac arrhythmia (children), cardiac failure (children), cerebrovascular disease, disseminated intravascular coagulation (children), hematoma, hemorrhage, hypersensitivity reaction, hypertension, hypoglycemia, orthostatic hypotension, peripheral ischemia, pharyngeal edema, pulmonary edema, pulmonary embolism, respiratory depression, seizure, shock</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183721\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intrathecal administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling</i>: Additional contraindications (not in US labeling): Hypersensitivity to iodixanol or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2087643\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contrast media reactions: Serious and life-threatening hypersensitivity reactions have occurred, including anaphylaxis. Use extreme caution with history of previous reaction to contrast dye, iodine-based contrast media or patients with a known clinical hypersensitivity (eg, bronchial asthma, hay fever, food allergies). Obtain allergy and hypersensitivity history prior to administration. Premedication with antihistamines or corticosteroids should be considered to reduce incidence and severity of reaction. Monitor closely during and for 30 to 60 minutes after administration (delayed reactions have occurred).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatological effects: Severe cutaneous adverse reactions (including Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN], acute generalized exanthematous pustulosis [AGEP], drug reaction with eosinophilia and systemic symptoms [DRESS]) have occurred 1 hour to several weeks after administration; reaction severity may increase and time to onset may decrease with repeat administration. Avoid use in patients with a history of a severe cutaneous adverse reaction to iodixanol.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant; ensure proper needle/catheter/line placement prior to and during administration. Avoid extravasation, particularly in patients with severe arterial or venous disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal failure: Acute renal failure may occur; has been reported in patients with hepatic impairment administered an oral cholecystographic agent followed by an intravascular iodinated radiocontrast agent. Preparatory dehydration may contribute to acute renal failure in infants, young children and elderly patients, patients with preexisting renal impairment, multiple myeloma, advanced vascular disease, and diabetes; avoid fluid restriction and maintain normal hydration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Use meticulous intravascular administration techniques, particularly during angiographic procedures. Ionic iodinated contrast media may inhibit blood coagulation (more than nonionic contrast media). Clotting has been reported when in vitro blood remains in contact with syringes containing nonionic contrast media; use of plastic syringes in place of glass syringes has been reported to decrease, but not eliminate, the likelihood of in vitro clotting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease and heart failure patients receiving concurrent diuretic therapy; they may have intravascular volume depletion, which may affect the renal response to the contrast agent osmotic load; observe such patients for several hours following the procedure to detect renal delayed hemodynamic renal function disturbances. Preparatory dehydration may contribute to acute renal failure in patients with advanced vascular disease; avoid fluid restriction and maintain normal hydration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Preparatory dehydration may contribute to acute renal failure in patients with diabetes; avoid fluid restriction and maintain normal hydration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment, and those with concomitant renal impairment, particularly when large doses are administered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Homocystinuria: Avoid angiography in patients with homocystinuria; may be at risk for thrombosis and embolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Thyroid storm following intravascular administration of iodinated contrast media have occurred in patients with hyperthyroidism or with an autonomously functioning thyroid nodule; use caution in severe thyrotoxicosis. Iodine-binding capacity of thyroid tissue may be reduced for at least 16 days following administration of contrast media for diagnosis of thyroid disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypothyroidism: Thyroid function tests indicative of hypothyroidism or transient thyroid suppression have been reported (uncommon) in adult and pediatric patients (including infants); some patients were treated for hypothyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple myeloma: Use with caution in patients with multiple myeloma or other paraproteinaceous diseases; use of intravascular contrast agents may lead to renal impairment, especially with concurrent dehydration. Partial dehydration in the preparation of these patients prior to injection is not recommended since this may predispose the patient to precipitation of the myeloma protein.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pheochromocytoma: Use with extreme caution in patients with pheochromocytoma (known or suspected). Dose injected should be kept to a minimum to minimize exposure; monitor blood pressure closely. Therapy to manage hypertensive crisis should be readily available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary disease: The risks of angiocardiography in patients with chronic pulmonary emphysema should be weighed against the necessity for the procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; combined renal and hepatic disease, combined renal and cardiac disease, or anuria; particularly when large doses are administered. Preparatory dehydration may contribute to acute renal failure in patients with preexisting renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sickle cell disease: Use with caution in patients with homozygous sickle cell disease; administration of contrast media may promote sickling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients with age-related renal patients. Preparatory dehydration may contribute to acute renal failure in elderly patients; maintain adequate hydration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Children may have an increased risk of adverse effects, especially patients with asthma, sensitivity to allergens or medications, dehydration, heart failure, or serum creatinine &gt;1.5 mg/dL. Preparatory dehydration may contribute to acute renal failure in infants and young children.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate administration: For intravascular use only. <b>[US Boxed Warning]:</b> <b>Not for intrathecal use</b>. <b>Inadvertent intrathecal administration may cause death, convulsions/seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Adequately hydrate patient prior to and following administration. Delay intravenous contrast agent administration in patients who have recently received a cholecystographic contrast agent. In contrast-enhanced computerized tomography, contrast may obscure some lesions previously seen on unenhanced CT scans.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i> Intravascular administration:</i> In angiographic procedures, during catheter manipulations and contrast medium injection, a possibility of dislodging plaques or damaging (or perforating) vessel walls with resultant pseudoaneurysms, hemorrhage at puncture site, or dissection of coronary artery exists. Ensure proper catheter placement with test injections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Trained personnel: Clinicians using radiopaque contrast agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use during and for 30 to 60 minutes after administration (delayed reactions have occurred).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26023249\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Use with caution in pediatric patients with asthma, hypersensitivity to other medication and/or allergens, cyanotic and acyanotic heart disease, CHF, serum creatinine &gt;1.5 mg/dL, and neonates (immature renal function) due to an increased risk of adverse effects with iodixanol. Dehydration, particularly in children, may also increase the risk of adverse effects. Patients should be adequately hydrated both prior to and after iodixanol administration. In pediatric patients, apnea, arrhythmias (AV block, bundle branch block), cardiac failure, disseminated intravascular coagulation, and taste perversion have been reported.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299528\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2087653\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12989&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Iodinated Contrast Agents may enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis.  Management: Management advice varies. Refer to the full drug interaction monograph content for details.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183723\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. In general, iodinated contrast media agents may cross the placenta; use should be avoided unless absolutely required to obtain diagnostic information that will influence the care of the mother or fetus during pregnancy (ACOG 2016; ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4150481\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor signs and symptoms of hypersensitivity reactions; blood pressure; hydration status</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2087657\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Opacifies vessels in the path of flow permitting radiographic imaging of internal structures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2087659\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Note:</b> Following administration, the increase in tissue density is related to blood flow, the concentration of the iodixanol solution used, and the extraction of iodixanol by various interstitial tissues. The degree of enhancement is directly related to the iodine content in an administered dose. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Onset of action: Kidney:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Visualization: Renal parenchyma: 30 to 60 seconds; calyces and pelves (normal renal function): 1 to 3 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Optimum contrast: 5 to 15 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Distribution: V<sub>d</sub>: 0.26 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: No</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Metabolites have not been demonstrated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients (Johnson 2001): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Newborns to Infants &lt;2 months: 4.1 &plusmn; 1.4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 2 to 6 months: 2.8 &plusmn; 0.6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 6 to 12 months: 2.4 &plusmn; 0.4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to &lt;3 years: 2.2 &plusmn; 0.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 3 to &lt;12 years: 2.3 &plusmn; 0.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 2.1 &plusmn; 0.1 hours; increased to 23 hours in renal impairment (mean CrCl: 13.61 &plusmn; 4.67 mL/minute)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: IV: 0.75 to 1.25 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Immediate; peak enhancement at 15 to 120 seconds; optimum renal contrast at 5 to 15 minutes; brain contrast at up to 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (97% within 24 hours); feces (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: Adults: 110 mL/minute </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323201\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Visipaque Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">270 mg/mL (100 mL): $120.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">320 mg/mL (50 mL): $66.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038659\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Dixanol 270 (BD);</li>\n      <li>Dixanol 320 (BD);</li>\n      <li>Visipaque (AE, AT, AU, BE, BG, CH, CN, CO, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HR, IE, IL, IS, JO, KR, KW, LK, LT, LU, LV, MT, NL, NO, PL, PT, QA, RU, SA, SE, SI, SK, TR, UY);</li>\n      <li>Vizypak (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Johnson WH, Lloyd TR, Victorica BE, et al, &ldquo;Iodixanol Pharmacokinetics in Children,&rdquo; <i>Pediatr Cardiol</i>, 2001, 22(3):223-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iodixanol-pediatric-drug-information/abstract-text/11343148/pubmed\" target=\"_blank\" id=\"11343148\">11343148</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCara ME. Extravasation: a hazard of intravenous therapy.<i> Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iodixanol-pediatric-drug-information/abstract-text/6628223 /pubmed\" target=\"_blank\" id=\"6628223 \">6628223 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowlett J. Extravasation of contrast media managed with recombinant human hyaluronidase. <i>Am J Emerg Med</i>. 2012;30(9):2102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iodixanol-pediatric-drug-information/abstract-text/22633726 /pubmed\" target=\"_blank\" id=\"22633726 \">22633726 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Visipaque (iodixanol) [prescribing information]. Princeton, NJ: GE Healthcare Inc; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12989 Version 89.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708949\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F183727\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9746694\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1019840\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F4150480\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F183718\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F183714\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2529683\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F183726\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1019841\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2087642\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F2087648\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F183721\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F2087643\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26023249\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299528\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F2087653\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F183723\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F4150481\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F2087657\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F2087659\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323201\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038659\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12989|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=iodixanol-drug-information\" class=\"drug drug_general\">Iodixanol: Drug information</a></li><li><a href=\"topic.htm?path=iodixanol-patient-drug-information\" class=\"drug drug_patient\">Iodixanol: Patient drug information</a></li></ul></div></div>","javascript":null}